Annovis Stock Valuation

ANVS -  USA Stock  

USD 13.04  0.49  3.62%

How much is Annovis Bio worth today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Annovis Bio, is its stock price multiplied by the total number of shares outstanding, calculating Annovis Bio's enterprise value requires a different approach. It uses Annovis Bio's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
As of 01/23/2022, Tangible Asset Value is likely to grow to about 10.1 M, while Free Cash Flow is likely to drop (3.7 M).
Annovis Bio shows a prevailing Real Value of $27.15 per share. The current price of the firm is $13.04. At this time, the firm appears to be undervalued. Our model approximates the value of Annovis Bio from analyzing the firm fundamentals such as Shares Owned by Insiders of 30.67 %, current valuation of 105.32 M, and Return On Equity of (36.93) % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor buying undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.

Annovis Valuation 

 
Refresh
Annovis Bio Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Annovis Bio's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today
13.04
23rd of January 2022
Share
Please note that Annovis Bio's price fluctuation is not too volatile at this time. Calculation of the real value of Annovis Bio is based on 3 months time horizon. Increasing Annovis Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Annovis Bio is useful when determining the fair value of the Annovis stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Annovis Bio. Since Annovis Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Annovis Stock. However, Annovis Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
27.15
Real Value
32.95
Upside
Estimating the potential upside or downside of Annovis Bio helps investors to forecast how Annovis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Annovis Bio more accurately as focusing exclusively on Annovis Bio's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimated ValueHigh
7.8613.6619.46
Details
1 Analysts
Consensus
LowTarget PriceHigh
70.0070.0070.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Annovis Bio's intrinsic value based on its ongoing forecasts of Annovis Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Annovis Bio's closest peers. When choosing an evaluation method for Annovis Bio, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Annovis Valuation Drivers Correlation

Many accounts on the financial statements of Annovis Bio are highly interrelated and sometimes correlated. Consequently, when conducting Annovis's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Annovis
Click cells to compare fundamentals

Annovis Valuation Trend

Knowing Annovis Bio's actual value is paramount for traders to make sound investment determinations. Annovis Bio's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Annovis Bio's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Annovis Bio's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Annovis Market Cap

Annovis Bio is number one stock in market capitalization category among related companies. Market capitalization of Biotechnology industry is presently estimated at about 129.57 Million. Annovis Bio totals roughly 105.63 Million in market capitalization claiming about 82% of stocks in Biotechnology industry.
Capitalization  Total debt  Workforce  Valuation  Revenue

Annovis Bio Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Annovis Bio's current stock value. Our valuation model uses many indicators to compare Annovis Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Annovis Bio competition to find correlations between indicators driving Annovis Bio's intrinsic value. More Info.
Annovis Bio is number one stock in price to book category among related companies. It is rated second in price to sales category among related companies fabricating about  1.03  of Price to Sales per Price to Book. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Annovis Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Annovis Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Annovis Bio's earnings, one of the primary drivers of an investment's value.

About Annovis Bio Valuation

The equity valuation mechanism determines the current worth of Annovis Bio on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Annovis Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Annovis Bio based exclusively on its fundamental and basic technical indicators. By analyzing Annovis Bio's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Annovis Bio's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Annovis Bio. We calculate exposure to Annovis Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Annovis Bio's related companies.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 2 people.

Annovis Bio Quarterly Enterprise Value

207.97 MillionShare

Annovis Bio Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Annovis Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio42.35

Annovis Bio Current Valuation Indicators

Valuation refers to the process of determining the present value of Annovis Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Annovis we look at many different elements of the entity such as Annovis's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Annovis Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Annovis Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Annovis Bio's worth.
Please continue to Trending Equities. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.